Dermal carcinogenicity in transgenic mice: Relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12-O- tetradecanoylphorbol 13-acetate (TPA) and benzene

Toxicologic Pathology

Volumn 26, Issue 4, 1998, Pages 541-547

  Blanchard, K T ^a   Ball, D J ^a   Holden, H E ^a   Furst, S M ^a   Stoltz, J H ^a   Stoll, R E ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Benzene; Dermal papillomas; Short term carcinogenicity tests; Tg.AC mice; TPA; Transgenic rodent lines

Indexed keywords

BENZENE; PHORBOL 13 ACETATE 12 MYRISTATE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CARCINOGEN TESTING; CONTROLLED STUDY; GENOME; HEMIZYGOSITY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RODENT; SKIN CARCINOGENESIS; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 0031824060     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339802600410     Document Type: Article

References (8)

1. Hansen L and Tennant RW (1994). Focal transgenic expression associated with papilloma development in v-Has-ras transgenic Tg.AC mice. Mol. Carcinog. 9: 143-156.
2. Holden HE, Stoll RE, Spalding JW, and Tennant RW (1998). Hemizygous Tg.AC transgenic mouse as a potential alternative to the 2-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors. J. Appl. Toxicol. 18: 19-24.
3. Leder A, Kuo A, Cardiff RD, Sinn E, and Leder P (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA 87: 9178-9182.
4. Spalding JW, Momma J, Elwell MR, and Tennant RW (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (Tg.AC) carrying a v-Has-ras gene. Carcinogenesis 14: 1335-1341.
5. Tennant R (1997). Identifying carcinogens - A strategy for use of abbreviated models. Toxicol. Pathol. 25: 240-241.
6. Tennant RW, French JE, and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103: 942-950.
7. Tennant RW, Spalding J, and French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat. Res. 365: 119-127.
8. Thompson KL, Rosenzweig BA, and Sistare FD (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol. Pathol. 26: 548-555 (this issue).